Stevens Johnson Syndrome — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for stevens johnson syndrome. 9 active patents protecting 1 drugs from 1+ originators. First major cliff: 2041. Daily refresh.

1
Approved drugs
9
Active US patents
72/100
Avg vulnerability
—
Annual revenue covered

Originators in Stevens Johnson Syndrome

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Mallinckrodt Ireland 9 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating stevens johnson syndrome. Each bar = one year. Y-axis scaled to peak year (1 patents).

No expiries in next 15 years.

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Acthar Gel
CORTICOTROPIN
 Mallinckrodt Ireland 9 72 — 2041-07-18

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
11752199 Acthar Gel method of use 75 2041-07-18
11752199 Acthar Gel method of use 75 2041-07-18
12440542 Acthar Gel method of use 75 2043-10-27
11975047 Acthar Gel method of use 75 2043-10-27
12102662 Acthar Gel method of use 75 2043-10-27
12102662 Acthar Gel method of use 75 2043-10-27
12233105 Acthar Gel method of use 75 2043-10-27
11752199 Acthar Gel method of use 70 2041-07-18
12324787 Acthar Gel formulation 55 2043-10-27

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
12324787 Acthar Gel formulation 55 2043-10-27
11752199 Acthar Gel method of use 70 2041-07-18
12440542 Acthar Gel method of use 75 2043-10-27
11975047 Acthar Gel method of use 75 2043-10-27
12102662 Acthar Gel method of use 75 2043-10-27
12102662 Acthar Gel method of use 75 2043-10-27
12233105 Acthar Gel method of use 75 2043-10-27
11752199 Acthar Gel method of use 75 2041-07-18
11752199 Acthar Gel method of use 75 2041-07-18

Related